Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Coordination and Support Action · Running

INTERCEPTOR INTERnational Cooperation of high containment research infrastructures: from Epidemic Preparedness TO Response

Coordinator
European Research Infrastructure on Highly Pathogenic Agents, Belgium
Runs
1 January 2024 to 31 December 2026
Status
Running
EU funding
€1.5m
Total cost
—
Partners
24 organisations in 20 countries
Type
Coordination and Support Action
Grant agreement
101132215

What the project is doing

In the project's own words, from its summary on CORDIS.

Emerging infectious diseases (EID) do not respect borders. They rank as global catastrophic risks for humanity, along with climate change and biodiversity loss. The COVID-19 pandemic showed how coordination of global research, through cooperation, and sharing of data and expertise, are crucial for efficient and effective preparedness to EIDs, and vital for a rapid response. Nevertheless, there are still major challenges limiting global cooperation among high containment laboratories (HCLs).

HCLs are critical infrastructures for the development of medical countermeasures (e.g., vaccines and therapeutics) against high consequence pathogens. In order to fulfil its role, and given the global threat of EIDs, the European Research Infrastructure on Highly pathogenic Agents (ERINHA), together with its partners, proposes to establish and reinforce interactions with HCL research infrastructures (RI) worldwide, to strengthen pandemic preparedness and response capacities.

INTERCEPTOR (INTERnational Cooperation of high containment research infrastructures: from Epidemic Preparedness TO Response), a consortium with key HCLs from Europe and across the world, will focus on access provision to HCLs, enhancement of the human capital of HCL, including in biorisk management, critical resources sharing, harmonisation and interoperability. The proposed actions will help ensure broader access to state-of-the-art HC facilities, while respecting the necessary biosecurity and biosafety constraints, and promote the establishment of a sustainable global network of HC RIs.

By expanding access to HC RIs, strengthening the human capital base, promoting sharing of knowledge, skills and experience, and providing opportunities for common training programmes and staff exchanges, INTERCEPTOR will reinforce the next generation of HCL researchers and facility managers, and extend the opportunities for access to HCLs, required to push the boundaries of science and innovation in the field of EIDs.

Topics

Who is involved

OrganisationCityCountryRole
European Research Infrastructure on Highly Pathogenic AgentsBruxelles / BrusselBelgiumCoordinator
Medizinische Universitat GrazGrazAustriaParticipant
Commonwealth Scientific and Industrial Research OrganisationActon ActAustraliaParticipant
Centro Nacional De Pesquisa Em Energia E Materias Associacao PrivadaCampinasBrazilAssociatedpartner
Fundacao Oswaldo CruzRio De JaneiroBrazilAssociatedpartner
University of SaskatchewanSaskatoonCanadaAssociatedpartner
Eidgenossisches Departement Fur Verteidigung, Bevolkerungsschutz Und SportBernSwitzerlandParticipant
Philipps Universitaet MarburgMarburgGermanyParticipant
Robert Koch-InstitutBerlinGermanyAssociatedpartner
Instituto De Salud Carlos IiiMadridSpainParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Nemzeti Nepegeszsegugyi Es Gyogyszereszeti KozpontBudapestHungaryParticipant
Pecsi Tudomanyegyetem - University of PecsPecsHungaryAssociatedpartner
Istituto Nazionale per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura a Carattere ScientificoRomaItalyParticipant
Institut Pasteur KoreaSeongnam-SiSouth KoreaAssociatedpartner
University of MalayaKuala LumpurMYAssociatedpartner
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsAssociatedpartner
Instituto Nacional De Saude Dr. Ricardo JorgeLisboaPortugalParticipant
FolkhalsomyndighetenSolnaSwedenParticipant
A*STAR Infectious Diseases LabsSingaporeSGAssociatedpartner
National University of Singapore Public Company Limited by GuaranteeSingaporeSGAssociatedpartner
Department of HealthLeedsUnited KingdomParticipant
The University of Texas Medical Branch at GalvestonGalvestonUnited StatesAssociatedpartner
National Health Laboratory ServicesSandringhamSouth AfricaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI